Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Arrhythmias

  Free Subscription


Articles published in Am Heart J

Retrieve available abstracts of 85 articles:
HTML format
Text format



Single Articles


    November 2017
  1. LIP GYH, Al-Saady N, Ezekowitz MD, Banach M, et al
    The relationship of renal function to outcome: A post hoc analysis from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
    Am Heart J. 2017;193:16-22.
    PubMed     Text format     Abstract available


    October 2017
  2. MOJOLI M, Gersh BJ, Barioli A, Masiero G, et al
    Impact of atrial fibrillation on outcomes of patients treated by transcatheter aortic valve implantation: A systematic review and meta-analysis.
    Am Heart J. 2017;192:64-75.
    PubMed     Text format     Abstract available


  3. KESSLER M, Gonska B, Seeger J, Rottbauer W, et al
    Predictors of permanent pacemaker implantation after transfemoral aortic valve implantation with the Lotus valve.
    Am Heart J. 2017;192:57-63.
    PubMed     Text format     Abstract available


  4. VINEREANU D, Al-Khalidi HR, Rao MP, He W, et al
    Regional differences in presentation and antithrombotic treatment of patients with atrial fibrillation: Baseline characteristics from a clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with atrial fibrillation (IMPACT-AF
    Am Heart J. 2017;192:38-47.
    PubMed     Text format     Abstract available


  5. FASHANU OE, Norby FL, Aguilar D, Ballantyne CM, et al
    Galectin-3 and incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study.
    Am Heart J. 2017;192:19-25.
    PubMed     Text format     Abstract available


    September 2017
  6. FRIEDMAN DJ, Al-Khatib SM, Zeitler EP, Han J, et al
    New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials.
    Am Heart J. 2017;191:21-29.
    PubMed     Text format     Abstract available


  7. O'NEILL ES, Grande SW, Sherman A, Elwyn G, et al
    Availability of patient decision aids for stroke prevention in atrial fibrillation: A systematic review.
    Am Heart J. 2017;191:1-11.
    PubMed     Text format     Abstract available


    August 2017
  8. HIJAZI Z, Oldgren J, Andersson U, Connolly SJ, et al
    Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
    Am Heart J. 2017;190:94-103.
    PubMed     Text format     Abstract available


  9. PROIETTI M, Airaksinen KEJ, Rubboli A, Schlitt A, et al
    Time in therapeutic range and major adverse outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention: The Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry.
    Am Heart J. 2017;190:86-93.
    PubMed     Text format     Abstract available


  10. BERNSTEIN RA, Kamel H, Granger CB, Kowal RC, et al
    Stroke of Known Cause and Underlying Atrial Fibrillation (STROKE-AF) randomized trial: Design and rationale.
    Am Heart J. 2017;190:19-24.
    PubMed     Text format     Abstract available


  11. KIRCHHOF P, Blank BF, Calvert M, Camm AJ, et al
    Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial.
    Am Heart J. 2017;190:12-18.
    PubMed     Text format     Abstract available


    July 2017
  12. PERINI AP, Kutyifa V, Veazie P, Daubert JP, et al
    Effects of implantable cardioverter/defibrillator shock and antitachycardia pacing on anxiety and quality of life: A MADIT-RIT substudy.
    Am Heart J. 2017;189:75-84.
    PubMed     Text format     Abstract available


  13. STEINBERG BA, Shrader P, Thomas L, Ansell J, et al
    Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Am Heart J. 2017;189:40-47.
    PubMed     Text format     Abstract available


  14. KUTYIFA V, Beck C, Brown MW, Cannom D, et al
    Multicenter Automatic Defibrillator Implantation Trial-Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol.
    Am Heart J. 2017;189:158-166.
    PubMed     Text format     Abstract available


  15. LOPES RD, Alings M, Connolly SJ, Beresh H, et al
    Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial.
    Am Heart J. 2017;189:137-145.
    PubMed     Text format     Abstract available


  16. HOLMES DR, Reddy VY, Buchbinder M, Stein K, et al
    The Assessment of the Watchman Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO) trial.
    Am Heart J. 2017;189:68-74.
    PubMed     Text format     Abstract available


    June 2017
  17. GRAVES KG, May HT, Jacobs V, Bair TL, et al
    Atrial fibrillation incrementally increases dementia risk across all CHADS2 and CHA2DS2VASc strata in patients receiving long-term warfarin.
    Am Heart J. 2017;188:93-98.
    PubMed     Text format     Abstract available


  18. GRAFF S, Prior A, Fenger-Gron M, Christensen B, et al
    Does perceived stress increase the risk of atrial fibrillation? A population-based cohort study in Denmark.
    Am Heart J. 2017;188:26-34.
    PubMed     Text format     Abstract available


    May 2017
  19. GEHI AK, Doros G, Glorioso TJ, Grunwald GK, et al
    Factors associated with rhythm control treatment decisions in patients with atrial fibrillation-Insights from the NCDR PINNACLE registry.
    Am Heart J. 2017;187:88-97.
    PubMed     Text format     Abstract available


  20. KARLSSON LO, Nilsson S, Charitakis E, Bang M, et al
    Clinical decision support for stroke prevention in atrial fibrillation (CDS-AF): Rationale and design of a cluster randomized trial in the primary care setting.
    Am Heart J. 2017;187:45-52.
    PubMed     Text format     Abstract available


  21. DIEDERICHSEN SZ, Haugan KJ, Kober L, Hojberg S, et al
    Atrial fibrillation detected by continuous electrocardiographic monitoring using implantable loop recorder to prevent stroke in individuals at risk (the LOOP study): Rationale and design of a large randomized controlled trial.
    Am Heart J. 2017;187:122-132.
    PubMed     Text format     Abstract available


  22. PICCINI JP, Clark RL, Kowey PR, Mittal S, et al
    Long-term electrocardiographic safety monitoring in clinical drug development: A report from the Cardiac Safety Research Consortium.
    Am Heart J. 2017;187:156-169.
    PubMed     Text format     Abstract available


    April 2017
  23. EGBE AC, Connolly HM, Khan AR, Niaz T, et al
    Outcomes in adult Fontan patients with atrial tachyarrhythmias.
    Am Heart J. 2017;186:12-20.
    PubMed     Text format     Abstract available


  24. WAN C, Szymkiewicz SJ, Klein HU
    The impact of body mass index on the wearable cardioverter defibrillator shock efficacy and patient wear time.
    Am Heart J. 2017;186:111-117.
    PubMed     Text format     Abstract available


    March 2017
  25. CHAMBERLAIN AM, Alonso A, Gersh BJ, Manemann SM, et al
    Multimorbidity and the risk of hospitalization and death in atrial fibrillation: A population-based study.
    Am Heart J. 2017;185:74-84.
    PubMed     Text format     Abstract available


  26. POKORNEY SD, Kim S, Thomas L, Fonarow GC, et al
    Cardioversion and subsequent quality of life and natural history of atrial fibrillation.
    Am Heart J. 2017;185:59-66.
    PubMed     Text format     Abstract available


  27. ROBINSON VM, Bharucha DB, Mahaffey KW, Dorian P, et al
    Results of a curtailed randomized controlled trial, evaluating the efficacy and safety of azimilide in patients with implantable cardioverter-defibrillators: The SHIELD-2 trial.
    Am Heart J. 2017;185:43-51.
    PubMed     Text format     Abstract available


  28. WESTENBRINK BD, Alings M, Granger CB, Alexander JH, et al
    Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
    Am Heart J. 2017;185:140-149.
    PubMed     Text format     Abstract available


  29. SMITH WM, Riddell F, Madon M, Gleva MJ, et al
    Comparison of diagnostic value using a small, single channel, P-wave centric sternal ECG monitoring patch with a standard 3-lead Holter system over 24 hours.
    Am Heart J. 2017;185:67-73.
    PubMed     Text format     Abstract available


  30. KUPSKY DF, Ahmed AM, Sakr S, Qureshi WT, et al
    Cardiorespiratory fitness and incident heart failure: The Henry Ford ExercIse Testing (FIT) Project.
    Am Heart J. 2017;185:35-42.
    PubMed     Text format     Abstract available


    February 2017
  31. ERNE P, Iglesias JF, Urban P, Eberli FR, et al
    Left bundle-branch block in patients with acute myocardial infarction: Presentation, treatment, and trends in outcome from 1997 to 2016 in routine clinical practice.
    Am Heart J. 2017;184:106-113.
    PubMed     Text format     Abstract available


  32. FANOLA CL, Mooney D, Cowan AJ, Ko D, et al
    Incidence of severe renal dysfunction among individuals taking warfarin and implications for non-vitamin K oral anticoagulants.
    Am Heart J. 2017;184:150-155.
    PubMed     Text format     Abstract available


  33. SORENSEN LL, Liang HY, Pinheiro A, Hilser A, et al
    Safety profile and utility of treadmill exercise in patients with high-gradient hypertrophic cardiomyopathy.
    Am Heart J. 2017;184:47-54.
    PubMed     Text format     Abstract available


    January 2017
  34. RAHMAN F, Himali JJ, Yin X, Beiser AS, et al
    Serum brain-derived neurotrophic factor and risk of atrial fibrillation.
    Am Heart J. 2017;183:69-73.
    PubMed     Text format     Abstract available


  35. DUDINK E, Essers B, Holvoet W, Weijs B, et al
    Acute cardioversion vs a wait-and-see approach for recent-onset symptomatic atrial fibrillation in the emergency department: Rationale and design of the randomized ACWAS trial.
    Am Heart J. 2017;183:49-53.
    PubMed     Text format     Abstract available


  36. OSMANCIK P, Tousek P, Herman D, Neuzil P, et al
    Interventional left atrial appendage closure vs novel anticoagulation agents in patients with atrial fibrillation indicated for long-term anticoagulation (PRAGUE-17 study).
    Am Heart J. 2017;183:108-114.
    PubMed     Text format     Abstract available


  37. EGBE AC, Connolly HM, Niaz T, Yogeswaran V, et al
    Prevalence and outcome of thrombotic and embolic complications in adults after Fontan operation.
    Am Heart J. 2017;183:10-17.
    PubMed     Text format     Abstract available


    December 2016
  38. RANDOLPH TC, Simon DN, Thomas L, Allen LA, et al
    Patient factors associated with quality of life in atrial fibrillation.
    Am Heart J. 2016;182:135-143.
    PubMed     Text format     Abstract available


    November 2016
  39. YAKSH A, Kik C, Knops P, van Ettinger MJ, et al
    Early, de novo atrial fibrillation after coronary artery bypass grafting: Facts and features.
    Am Heart J. 2016;184:62-70.
    PubMed     Text format     Abstract available


  40. PROIETTI M, Laroche C, Drozd M, Vijgen J, et al
    Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry.
    Am Heart J. 2016;181:83-91.
    PubMed     Text format     Abstract available


  41. STEINBERG BA, Shrader P, Kim S, Thomas L, et al
    How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).
    Am Heart J. 2016;181:145-152.
    PubMed     Text format     Abstract available


  42. RISOM SS, Zwisler AD, Rasmussen TB, Sibilitz KL, et al
    Cardiac rehabilitation versus usual care for patients treated with catheter ablation for atrial fibrillation: Results of the randomized CopenHeartRFA trial.
    Am Heart J. 2016;181:120-129.
    PubMed     Text format     Abstract available


    October 2016
  43. VAN DER MEERSCH H, De Bacquer D, De Vriese AS
    Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis.
    Am Heart J. 2016;184:37-46.
    PubMed     Text format     Abstract available


    September 2016
  44. BUCK J, Kaboli P, Gage BF, Cram P, et al
    Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System.
    Am Heart J. 2016;179:186-91.
    PubMed     Text format     Abstract available


  45. CAIRNS JA
    Oral anticoagulant prescription for atrial fibrillation in the Veterans Administration Health System: National and international differences.
    Am Heart J. 2016;179:184-5.
    PubMed     Text format    


  46. THUNE JJ, Pehrson S, Nielsen JC, Haarbo J, et al
    Rationale, design, and baseline characteristics of the DANish randomized, controlled, multicenter study to assess the efficacy of Implantable cardioverter defibrillators in patients with non-ischemic Systolic Heart failure on mortality (DANISH).
    Am Heart J. 2016;179:136-41.
    PubMed     Text format     Abstract available


  47. SHAH R, Hellkamp A, Lokhnygina Y, Becker RC, et al
    Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
    Am Heart J. 2016;179:77-86.
    PubMed     Text format     Abstract available


  48. EZEKOWITZ MD, Pollack CV, Sanders P, Halperin JL, et al
    Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial.
    Am Heart J. 2016;179:59-68.
    PubMed     Text format     Abstract available


  49. GILOTRA NA, Bennett MK, Shpigel A, Ahmed HM, et al
    Outcomes and predictors of recovery in acute-onset cardiomyopathy: A single-center experience of patients undergoing endomyocardial biopsy for new heart failure.
    Am Heart J. 2016;179:116-26.
    PubMed     Text format     Abstract available


    August 2016
  50. MARTINS RP, Galand V, Colette E, Behar N, et al
    Defining nonvalvular atrial fibrillation: A quest for clarification.
    Am Heart J. 2016;178:161-7.
    PubMed     Text format     Abstract available


  51. LIP GY, Hammerstingl C, Marin F, Cappato R, et al
    Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF).
    Am Heart J. 2016;178:126-34.
    PubMed     Text format     Abstract available


  52. TABBALAT RA, Hamad NM, Alhaddad IA, Hammoudeh A, et al
    Effect of ColchiciNe on the InciDence of Atrial Fibrillation in Open Heart Surgery Patients: END-AF Trial.
    Am Heart J. 2016;178:102-7.
    PubMed     Text format     Abstract available


  53. VEMULAPALLI S, Hellkamp AS, Jones WS, Piccini JP, et al
    Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial.
    Am Heart J. 2016;178:74-84.
    PubMed     Text format     Abstract available


  54. CHRISTOPHERSEN IE, Yin X, Larson MG, Lubitz SA, et al
    A comparison of the CHARGE-AF and the CHA2DS2-VASc risk scores for prediction of atrial fibrillation in the Framingham Heart Study.
    Am Heart J. 2016;178:45-54.
    PubMed     Text format     Abstract available


  55. O'DONNELL MJ, Eikelboom JW, Yusuf S, Diener HC, et al
    Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study.
    Am Heart J. 2016;178:145-50.
    PubMed     Text format     Abstract available


    July 2016
  56. KIM EJ, Yin X, Fontes JD, Magnani JW, et al
    Atrial fibrillation without comorbidities: Prevalence, incidence and prognosis (from the Framingham Heart Study).
    Am Heart J. 2016;177:138-44.
    PubMed     Text format     Abstract available


  57. TING R, Tejpal A, Finken L, Fisher M, et al
    Repatriation to referral hospital after reperfusion of STEMI patients transferred for primary percutaneous coronary intervention: Insights of a Canadian regional STEMI care system.
    Am Heart J. 2016;177:145-52.
    PubMed     Text format     Abstract available


    June 2016
  58. RAO MP, Ciobanu AO, Lopes RD, Fox KA, et al
    A clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AF): design and rationale.
    Am Heart J. 2016;176:107-13.
    PubMed     Text format     Abstract available


  59. SCHNABEL RB, Maas R, Wang N, Yin X, et al
    Asymmetric dimethylarginine, related arginine derivatives, and incident atrial fibrillation.
    Am Heart J. 2016;176:100-6.
    PubMed     Text format     Abstract available


  60. RODRIGUEZ F, Stefanick ML, Greenland P, Soliman EZ, et al
    Racial and ethnic differences in atrial fibrillation risk factors and predictors in women: Findings from the Women's Health Initiative.
    Am Heart J. 2016;176:70-7.
    PubMed     Text format     Abstract available


  61. ECKMAN MH, Lip GY, Wise RE, Speer B, et al
    Impact of an Atrial Fibrillation Decision Support Tool on thromboprophylaxis for atrial fibrillation.
    Am Heart J. 2016;176:17-27.
    PubMed     Text format     Abstract available


  62. LOPES RD, de Paola AA, Lorga Filho AM, Consolim-Colombo FM, et al
    Rationale and design of the First Brazilian Cardiovascular Registry of Atrial Fibrillation: The RECALL study.
    Am Heart J. 2016;176:10-6.
    PubMed     Text format     Abstract available


    May 2016
  63. DE CATERINA R, Andersson U, Alexander JH, Al-Khatib SM, et al
    History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
    Am Heart J. 2016;175:175-83.
    PubMed     Text format     Abstract available


  64. GOODMAN SG
    Prior bleeding, future bleeding and stroke risk with oral anticoagulation in atrial fibrillation: What new lessons can ARISTOTLE teach us?
    Am Heart J. 2016;175:168-71.
    PubMed     Text format    


  65. STEINHUBL SR, Mehta RR, Ebner GS, Ballesteros MM, et al
    Rationale and design of a home-based trial using wearable sensors to detect asymptomatic atrial fibrillation in a targeted population: The mHealth Screening To Prevent Strokes (mSToPS) trial.
    Am Heart J. 2016;175:77-85.
    PubMed     Text format     Abstract available


  66. GUNDLUND A, Fosbol EL, Kim S, Fonarow GC, et al
    Family history of atrial fibrillation is associated with earlier-onset and more symptomatic atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.
    Am Heart J. 2016;175:28-35.
    PubMed     Text format     Abstract available


  67. ROBERTS JD, Dewland TA, Glidden DV, Hoffmann TJ, et al
    Impact of genetic variants on the upstream efficacy of renin-angiotensin system inhibitors for the prevention of atrial fibrillation.
    Am Heart J. 2016;175:9-17.
    PubMed     Text format     Abstract available


    April 2016
  68. DE VRIESE AS, Caluwe R, Raggi P
    The atrial fibrillation conundrum in dialysis patients.
    Am Heart J. 2016;174:111-9.
    PubMed     Text format     Abstract available


  69. GOLWALA H, Jackson LR 2nd, Simon DN, Piccini JP, et al
    Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry.
    Am Heart J. 2016;174:29-36.
    PubMed     Text format     Abstract available


    March 2016
  70. TRAN C, Bennell MC, Qiu F, Ko DT, et al
    Predictors and clinical outcomes of inpatient versus ambulatory management after an emergency department visit for atrial fibrillation: A population-based study.
    Am Heart J. 2016;173:161-9.
    PubMed     Text format     Abstract available


  71. MCALISTER FA, Rowe BH
    Variations in the emergency department management of atrial fibrillation: Lessons to be learned.
    Am Heart J. 2016;173:159-60.
    PubMed     Text format    


  72. ZIFF OJ, Camm AJ
    Individualized approaches to thromboprophylaxis in atrial fibrillation.
    Am Heart J. 2016;173:143-58.
    PubMed     Text format     Abstract available


  73. BERKOVITCH A, Kivity S, Klempfner R, Segev S, et al
    Body mass index and the risk of new-onset atrial fibrillation in middle-aged adults.
    Am Heart J. 2016;173:41-8.
    PubMed     Text format     Abstract available


  74. ESSEBAG V, Healey JS, Ayala-Paredes F, Kalfon E, et al
    Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial.
    Am Heart J. 2016;173:102-7.
    PubMed     Text format     Abstract available


    February 2016
  75. EISEN A, Giugliano RP, Ruff CT, Nordio F, et al
    Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myoc
    Am Heart J. 2016;172:144-51.
    PubMed     Text format     Abstract available


  76. HOEKSTRA M, Hessels L, Rienstra M, Yeh L, et al
    Computer-guided normal-low versus normal-high potassium control after cardiac surgery: No impact on atrial fibrillation or atrial flutter.
    Am Heart J. 2016;172:45-52.
    PubMed     Text format     Abstract available


  77. HAEUSLER KG, Kirchhof P, Heuschmann PU, Laufs U, et al
    Impact of standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke (MonDAFIS): Rationale and design of a prospective randomized multicenter study.
    Am Heart J. 2016;172:19-25.
    PubMed     Text format     Abstract available


    January 2016
  78. AL-HIJJI MA, Deshmukh AJ, Yao X, Mwangi R, et al
    Trends and predictors of repeat catheter ablation for atrial fibrillation.
    Am Heart J. 2016;171:48-55.
    PubMed     Text format     Abstract available


  79. POKORNEY SD, Radder C, Schulte PJ, Al-Khatib SM, et al
    High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction.
    Am Heart J. 2016;171:25-32.
    PubMed     Text format     Abstract available


    December 2015
  80. MEYERS HP, Limkakeng AT Jr, Jaffa EJ, Patel A, et al
    Validation of the modified Sgarbossa criteria for acute coronary occlusion in the setting of left bundle branch block: A retrospective case-control study.
    Am Heart J. 2015;170:1255-64.
    PubMed     Text format     Abstract available


  81. CHANDRASEKHAR J, Mastoris I, Baber U, Sartori S, et al
    Antithrombotic strategy variability in ATrial fibrillation and obstructive coronary disease revascularized with PCI-rationale and study design of the prospective observational multicenter AVIATOR 2 registry.
    Am Heart J. 2015;170:1234-42.
    PubMed     Text format     Abstract available


  82. LEE RJ, Lakkireddy D, Mittal S, Ellis C, et al
    Percutaneous alternative to the Maze procedure for the treatment of persistent or long-standing persistent atrial fibrillation (aMAZE trial): Rationale and design.
    Am Heart J. 2015;170:1184-94.
    PubMed     Text format     Abstract available


  83. AULIN J, Siegbahn A, Hijazi Z, Ezekowitz MD, et al
    Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation.
    Am Heart J. 2015;170:1151-60.
    PubMed     Text format     Abstract available


  84. MAGNUSON EA, Vilain K, Wang K, Li H, et al
    Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trial.
    Am Heart J. 2015;170:1140-50.
    PubMed     Text format     Abstract available


  85. VAKIL KP, Roukoz H, Tung R, Levy WC, et al
    Mortality prediction using a modified Seattle Heart Failure Model may improve patient selection for ventricular tachycardia ablation.
    Am Heart J. 2015;170:1099-104.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Arrhythmias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: